{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166122806",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166122806",
  "name" : "CPIC Guideline for phenytoin and CYP2C9,HLA-B",
  "groups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128867",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128867",
    "name" : "CYP2C9 Extensive metabolizer",
    "annotations" : [ {
      "id" : 1446426268,
      "text" : "Normal phenytoin metabolism.",
      "textHtml" : "<p>Normal phenytoin metabolism.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1446432108,
      "text" : "Extensive metabolizer (normal activity) (constitutes ~91% of patients)",
      "textHtml" : "<p>Extensive metabolizer (normal activity) (constitutes ~91% of patients)</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "src" : "guidelineTags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926"
      }
    }, {
      "id" : 1446426250,
      "text" : "An individual carrying two normal activity alleles.",
      "textHtml" : "<p>An individual carrying two normal activity alleles.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1446426305,
      "text" : "Initiate therapy with recommended maintenance dose (based on patient’s clinical characteristics).",
      "textHtml" : "<p>Initiate therapy with recommended maintenance dose (based on patient’s clinical characteristics).</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "CYP2C9:*1/*1;HLA-B:Other/Other", "CYP2C9:*1/*9;HLA-B:Other/Other", "CYP2C9:*9/*9;HLA-B:Other/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "src" : "guidelineStrength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128868",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128868",
    "name" : "CYP2C9 Intermediate metabolizer",
    "annotations" : [ {
      "id" : 1446426426,
      "text" : "Reduced phenytoin metabolism; higher plasma concentrations will increase probability of toxicities.",
      "textHtml" : "<p>Reduced phenytoin metabolism; higher plasma concentrations will increase probability of toxicities.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1446432122,
      "text" : "Intermediate metabolizer (intermediate activity) (constitutes ~8% of patients)",
      "textHtml" : "<p>Intermediate metabolizer (intermediate activity) (constitutes ~8% of patients)</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "src" : "guidelineTags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926"
      }
    }, {
      "id" : 1446426378,
      "text" : "An individual carrying one normal activity allele plus one decreased or no function allele.",
      "textHtml" : "<p>An individual carrying one normal activity allele plus one decreased or no function allele.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1446426474,
      "text" : "Consider 25% reduction of recommended starting maintenance dosed (based on patient’s clinical characteristics). Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.",
      "textHtml" : "<p>Consider 25% reduction of recommended starting maintenance dosed (based on patient’s clinical characteristics). Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "CYP2C9:*1/*15;HLA-B:Other/Other", "CYP2C9:*1/*25;HLA-B:Other/Other", "CYP2C9:*1/*2;HLA-B:Other/Other", "CYP2C9:*1/*3;HLA-B:Other/Other", "CYP2C9:*1/*6;HLA-B:Other/Other", "CYP2C9:*15/*9;HLA-B:Other/Other", "CYP2C9:*2/*9;HLA-B:Other/Other", "CYP2C9:*25/*9;HLA-B:Other/Other", "CYP2C9:*3/*9;HLA-B:Other/Other", "CYP2C9:*6/*9;HLA-B:Other/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501931",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501931,
      "src" : "guidelineStrength",
      "term" : "Moderate",
      "termId" : "guidelineStrength:981501931"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128869",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128869",
    "name" : "CYP2C9 Poor metabolizer",
    "annotations" : [ {
      "id" : 1446426511,
      "text" : "Reduced phenytoin metabolism; higher plasma concentrations will increase probability of toxicities.",
      "textHtml" : "<p>Reduced phenytoin metabolism; higher plasma concentrations will increase probability of toxicities.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1446432134,
      "text" : "Poor metabolizer (low or deficient activity) (constitutes ~1% of patients)",
      "textHtml" : "<p>Poor metabolizer (low or deficient activity) (constitutes ~1% of patients)</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "src" : "guidelineTags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926"
      }
    }, {
      "id" : 1446426488,
      "text" : "An individual carrying two decreased function alleles, or two no function alleles, or one decreased function allele and one no function allele.",
      "textHtml" : "<p>An individual carrying two decreased function alleles, or two no function alleles, or one decreased function allele and one no function allele.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1446426541,
      "text" : "Consider 50% reduction of recommended starting maintenance dose (based on patient’s clinical characteristics). Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.",
      "textHtml" : "<p>Consider 50% reduction of recommended starting maintenance dose (based on patient’s clinical characteristics). Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "CYP2C9:*15/*15;HLA-B:Other/Other", "CYP2C9:*15/*25;HLA-B:Other/Other", "CYP2C9:*15/*2;HLA-B:Other/Other", "CYP2C9:*15/*3;HLA-B:Other/Other", "CYP2C9:*15/*6;HLA-B:Other/Other", "CYP2C9:*2/*25;HLA-B:Other/Other", "CYP2C9:*2/*2;HLA-B:Other/Other", "CYP2C9:*2/*3;HLA-B:Other/Other", "CYP2C9:*2/*6;HLA-B:Other/Other", "CYP2C9:*25/*25;HLA-B:Other/Other", "CYP2C9:*25/*3;HLA-B:Other/Other", "CYP2C9:*25/*6;HLA-B:Other/Other", "CYP2C9:*3/*3;HLA-B:Other/Other", "CYP2C9:*3/*6;HLA-B:Other/Other", "CYP2C9:*6/*6;HLA-B:Other/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "src" : "guidelineStrength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128871",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128871",
    "name" : "CYP2C9 Possible Intermediate Metabolizer",
    "annotations" : [ {
      "id" : 1446432560,
      "text" : "Reduced phenytoin metabolism; higher plasma concentrations will increase probability of toxicities.",
      "textHtml" : "<p>Reduced phenytoin metabolism; higher plasma concentrations will increase probability of toxicities.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1446432595,
      "text" : "Possible intermediate metabolizer",
      "textHtml" : "<p>Possible intermediate metabolizer</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "src" : "guidelineTags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926"
      }
    }, {
      "id" : 1446432639,
      "text" : "An individual carrying one normal activity allele plus one possibly decreased function allele.",
      "textHtml" : "<p>An individual carrying one normal activity allele plus one possibly decreased function allele.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1446432801,
      "text" : "Due to the presence of a _possibly_ decreased function allele in combination with a normal function allele, this diplotype has been assigned as a _possible_ intermediate metabolizer. The CPIC dosing guideline recommendation for phenytoin for intermediate metabolizers is: Consider 25% reduction of recommended starting maintenance dosed (based on patient’s clinical characteristics). Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.",
      "textHtml" : "<p>Due to the presence of a <em>possibly</em> decreased function allele in combination with a normal function allele, this diplotype has been assigned as a <em>possible</em> intermediate metabolizer. The CPIC dosing guideline recommendation for phenytoin for intermediate metabolizers is: Consider 25% reduction of recommended starting maintenance dosed (based on patient’s clinical characteristics). Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "CYP2C9:*1/*11;HLA-B:Other/Other", "CYP2C9:*1/*12;HLA-B:Other/Other", "CYP2C9:*1/*13;HLA-B:Other/Other", "CYP2C9:*1/*31;HLA-B:Other/Other", "CYP2C9:*1/*4;HLA-B:Other/Other", "CYP2C9:*1/*5;HLA-B:Other/Other", "CYP2C9:*1/*8;HLA-B:Other/Other", "CYP2C9:*11/*9;HLA-B:Other/Other", "CYP2C9:*12/*9;HLA-B:Other/Other", "CYP2C9:*13/*9;HLA-B:Other/Other", "CYP2C9:*31/*9;HLA-B:Other/Other", "CYP2C9:*4/*9;HLA-B:Other/Other", "CYP2C9:*5/*9;HLA-B:Other/Other", "CYP2C9:*8/*9;HLA-B:Other/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "src" : "guidelineStrength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128870",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128870",
    "name" : "CYP2C9 Possible Poor Metabolizer",
    "annotations" : [ {
      "id" : 1446429968,
      "text" : "Reduced phenytoin metabolism; higher plasma concentrations will increase probability of toxicities.",
      "textHtml" : "<p>Reduced phenytoin metabolism; higher plasma concentrations will increase probability of toxicities.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1446432150,
      "text" : "Possible poor metabolizer",
      "textHtml" : "<p>Possible poor metabolizer</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "src" : "guidelineTags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926"
      }
    }, {
      "id" : 1446429950,
      "text" : "An individual carrying one of the following allele combinations: (1) two possibly decreased function alleles, (2) one possibly decreased function allele and one decreased function allele, (3) one possibly decreased function allele and one no function allele.",
      "textHtml" : "<p>An individual carrying one of the following allele combinations: (1) two possibly decreased function alleles, (2) one possibly decreased function allele and one decreased function allele, (3) one possibly decreased function allele and one no function allele.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1446429994,
      "text" : "Due to the presence of at least one _possibly_ decreased function allele, this diplotype has been assigned as a _possible_ poor metabolizer.  The CPIC dosing guideline recommendation for phenytoin for poor metabolizers is: Consider 50% reduction of recommended starting maintenance dose (based on patient’s clinical characteristics). Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.",
      "textHtml" : "<p>Due to the presence of at least one <em>possibly</em> decreased function allele, this diplotype has been assigned as a <em>possible</em> poor metabolizer.  The CPIC dosing guideline recommendation for phenytoin for poor metabolizers is: Consider 50% reduction of recommended starting maintenance dose (based on patient’s clinical characteristics). Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "CYP2C9:*11/*11;HLA-B:Other/Other", "CYP2C9:*11/*12;HLA-B:Other/Other", "CYP2C9:*11/*13;HLA-B:Other/Other", "CYP2C9:*11/*15;HLA-B:Other/Other", "CYP2C9:*11/*25;HLA-B:Other/Other", "CYP2C9:*11/*2;HLA-B:Other/Other", "CYP2C9:*11/*31;HLA-B:Other/Other", "CYP2C9:*11/*3;HLA-B:Other/Other", "CYP2C9:*11/*4;HLA-B:Other/Other", "CYP2C9:*11/*5;HLA-B:Other/Other", "CYP2C9:*11/*6;HLA-B:Other/Other", "CYP2C9:*11/*8;HLA-B:Other/Other", "CYP2C9:*12/*12;HLA-B:Other/Other", "CYP2C9:*12/*13;HLA-B:Other/Other", "CYP2C9:*12/*15;HLA-B:Other/Other", "CYP2C9:*12/*25;HLA-B:Other/Other", "CYP2C9:*12/*2;HLA-B:Other/Other", "CYP2C9:*12/*31;HLA-B:Other/Other", "CYP2C9:*12/*3;HLA-B:Other/Other", "CYP2C9:*12/*4;HLA-B:Other/Other", "CYP2C9:*12/*5;HLA-B:Other/Other", "CYP2C9:*12/*6;HLA-B:Other/Other", "CYP2C9:*12/*8;HLA-B:Other/Other", "CYP2C9:*13/*13;HLA-B:Other/Other", "CYP2C9:*13/*15;HLA-B:Other/Other", "CYP2C9:*13/*25;HLA-B:Other/Other", "CYP2C9:*13/*2;HLA-B:Other/Other", "CYP2C9:*13/*31;HLA-B:Other/Other", "CYP2C9:*13/*3;HLA-B:Other/Other", "CYP2C9:*13/*4;HLA-B:Other/Other", "CYP2C9:*13/*5;HLA-B:Other/Other", "CYP2C9:*13/*6;HLA-B:Other/Other", "CYP2C9:*13/*8;HLA-B:Other/Other", "CYP2C9:*15/*31;HLA-B:Other/Other", "CYP2C9:*15/*4;HLA-B:Other/Other", "CYP2C9:*15/*5;HLA-B:Other/Other", "CYP2C9:*15/*8;HLA-B:Other/Other", "CYP2C9:*2/*31;HLA-B:Other/Other", "CYP2C9:*2/*4;HLA-B:Other/Other", "CYP2C9:*2/*5;HLA-B:Other/Other", "CYP2C9:*2/*8;HLA-B:Other/Other", "CYP2C9:*25/*31;HLA-B:Other/Other", "CYP2C9:*25/*4;HLA-B:Other/Other", "CYP2C9:*25/*5;HLA-B:Other/Other", "CYP2C9:*25/*8;HLA-B:Other/Other", "CYP2C9:*3/*31;HLA-B:Other/Other", "CYP2C9:*3/*4;HLA-B:Other/Other", "CYP2C9:*3/*5;HLA-B:Other/Other", "CYP2C9:*3/*8;HLA-B:Other/Other", "CYP2C9:*31/*31;HLA-B:Other/Other", "CYP2C9:*31/*4;HLA-B:Other/Other", "CYP2C9:*31/*5;HLA-B:Other/Other", "CYP2C9:*31/*6;HLA-B:Other/Other", "CYP2C9:*31/*8;HLA-B:Other/Other", "CYP2C9:*4/*4;HLA-B:Other/Other", "CYP2C9:*4/*5;HLA-B:Other/Other", "CYP2C9:*4/*6;HLA-B:Other/Other", "CYP2C9:*4/*8;HLA-B:Other/Other", "CYP2C9:*5/*5;HLA-B:Other/Other", "CYP2C9:*5/*6;HLA-B:Other/Other", "CYP2C9:*5/*8;HLA-B:Other/Other", "CYP2C9:*6/*8;HLA-B:Other/Other", "CYP2C9:*8/*8;HLA-B:Other/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "src" : "guidelineStrength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128866",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128866",
    "name" : "HLA-B*15:02 positive",
    "annotations" : [ {
      "id" : 1446426066,
      "text" : "Increased risk of phenytoin-induced SJS/TEN.",
      "textHtml" : "<p>Increased risk of phenytoin-induced SJS/TEN. </p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1446426164,
      "text" : "Heterozygote or homozygous HLA-B*15:02 variant; at significantly increased risk of phenytoin-associated cutaneous adverse reactions (constitutes ~ 1.4% of patients).",
      "textHtml" : "<p>Heterozygote or homozygous HLA-B*15:02 variant; at significantly increased risk of phenytoin-associated cutaneous adverse reactions (constitutes ~ 1.4% of patients).</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1446426118,
      "text" : "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin.\r\n\r\nIf patient has previously used phenytoin for longer than 3 months without incidence of cutaneous adverse reactions, reinitiate phenytoin with caution.\r\n\r\nNote that carbamazepine should not be used as an alternative. Alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele and thus caution should be used in choosing alternatives to phenytoin (see guideline supplement for details).",
      "textHtml" : "<p>If patient is phenytoin-naive, do not use phenytoin/fosphenytoin.</p><p>If patient has previously used phenytoin for longer than 3 months without incidence of cutaneous adverse reactions, reinitiate phenytoin with caution.</p><p>Note that carbamazepine should not be used as an alternative. Alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele and thus caution should be used in choosing alternatives to phenytoin (see guideline supplement for details).</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "CYP2C9:*1/*11;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*11;HLA-B:*15:02:01/Other", "CYP2C9:*1/*12;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*12;HLA-B:*15:02:01/Other", "CYP2C9:*1/*13;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*13;HLA-B:*15:02:01/Other", "CYP2C9:*1/*15;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*15;HLA-B:*15:02:01/Other", "CYP2C9:*1/*1;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*1;HLA-B:*15:02:01/Other", "CYP2C9:*1/*25;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*25;HLA-B:*15:02:01/Other", "CYP2C9:*1/*2;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*2;HLA-B:*15:02:01/Other", "CYP2C9:*1/*31;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*31;HLA-B:*15:02:01/Other", "CYP2C9:*1/*3;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*3;HLA-B:*15:02:01/Other", "CYP2C9:*1/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*4;HLA-B:*15:02:01/Other", "CYP2C9:*1/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*5;HLA-B:*15:02:01/Other", "CYP2C9:*1/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*6;HLA-B:*15:02:01/Other", "CYP2C9:*1/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*8;HLA-B:*15:02:01/Other", "CYP2C9:*1/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*1/*9;HLA-B:*15:02:01/Other", "CYP2C9:*11/*11;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*11;HLA-B:*15:02:01/Other", "CYP2C9:*11/*12;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*12;HLA-B:*15:02:01/Other", "CYP2C9:*11/*13;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*13;HLA-B:*15:02:01/Other", "CYP2C9:*11/*15;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*15;HLA-B:*15:02:01/Other", "CYP2C9:*11/*25;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*25;HLA-B:*15:02:01/Other", "CYP2C9:*11/*2;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*2;HLA-B:*15:02:01/Other", "CYP2C9:*11/*31;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*31;HLA-B:*15:02:01/Other", "CYP2C9:*11/*3;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*3;HLA-B:*15:02:01/Other", "CYP2C9:*11/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*4;HLA-B:*15:02:01/Other", "CYP2C9:*11/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*5;HLA-B:*15:02:01/Other", "CYP2C9:*11/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*6;HLA-B:*15:02:01/Other", "CYP2C9:*11/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*8;HLA-B:*15:02:01/Other", "CYP2C9:*11/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*11/*9;HLA-B:*15:02:01/Other", "CYP2C9:*12/*12;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*12;HLA-B:*15:02:01/Other", "CYP2C9:*12/*13;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*13;HLA-B:*15:02:01/Other", "CYP2C9:*12/*15;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*15;HLA-B:*15:02:01/Other", "CYP2C9:*12/*25;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*25;HLA-B:*15:02:01/Other", "CYP2C9:*12/*2;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*2;HLA-B:*15:02:01/Other", "CYP2C9:*12/*31;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*31;HLA-B:*15:02:01/Other", "CYP2C9:*12/*3;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*3;HLA-B:*15:02:01/Other", "CYP2C9:*12/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*4;HLA-B:*15:02:01/Other", "CYP2C9:*12/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*5;HLA-B:*15:02:01/Other", "CYP2C9:*12/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*6;HLA-B:*15:02:01/Other", "CYP2C9:*12/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*8;HLA-B:*15:02:01/Other", "CYP2C9:*12/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*12/*9;HLA-B:*15:02:01/Other", "CYP2C9:*13/*13;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*13;HLA-B:*15:02:01/Other", "CYP2C9:*13/*15;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*15;HLA-B:*15:02:01/Other", "CYP2C9:*13/*25;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*25;HLA-B:*15:02:01/Other", "CYP2C9:*13/*2;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*2;HLA-B:*15:02:01/Other", "CYP2C9:*13/*31;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*31;HLA-B:*15:02:01/Other", "CYP2C9:*13/*3;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*3;HLA-B:*15:02:01/Other", "CYP2C9:*13/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*4;HLA-B:*15:02:01/Other", "CYP2C9:*13/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*5;HLA-B:*15:02:01/Other", "CYP2C9:*13/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*6;HLA-B:*15:02:01/Other", "CYP2C9:*13/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*8;HLA-B:*15:02:01/Other", "CYP2C9:*13/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*13/*9;HLA-B:*15:02:01/Other", "CYP2C9:*15/*15;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*15;HLA-B:*15:02:01/Other", "CYP2C9:*15/*25;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*25;HLA-B:*15:02:01/Other", "CYP2C9:*15/*2;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*2;HLA-B:*15:02:01/Other", "CYP2C9:*15/*31;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*31;HLA-B:*15:02:01/Other", "CYP2C9:*15/*3;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*3;HLA-B:*15:02:01/Other", "CYP2C9:*15/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*4;HLA-B:*15:02:01/Other", "CYP2C9:*15/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*5;HLA-B:*15:02:01/Other", "CYP2C9:*15/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*6;HLA-B:*15:02:01/Other", "CYP2C9:*15/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*8;HLA-B:*15:02:01/Other", "CYP2C9:*15/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*15/*9;HLA-B:*15:02:01/Other", "CYP2C9:*2/*25;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*2/*25;HLA-B:*15:02:01/Other", "CYP2C9:*2/*2;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*2/*2;HLA-B:*15:02:01/Other", "CYP2C9:*2/*31;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*2/*31;HLA-B:*15:02:01/Other", "CYP2C9:*2/*3;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*2/*3;HLA-B:*15:02:01/Other", "CYP2C9:*2/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*2/*4;HLA-B:*15:02:01/Other", "CYP2C9:*2/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*2/*5;HLA-B:*15:02:01/Other", "CYP2C9:*2/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*2/*6;HLA-B:*15:02:01/Other", "CYP2C9:*2/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*2/*8;HLA-B:*15:02:01/Other", "CYP2C9:*2/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*2/*9;HLA-B:*15:02:01/Other", "CYP2C9:*25/*25;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*25/*25;HLA-B:*15:02:01/Other", "CYP2C9:*25/*31;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*25/*31;HLA-B:*15:02:01/Other", "CYP2C9:*25/*3;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*25/*3;HLA-B:*15:02:01/Other", "CYP2C9:*25/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*25/*4;HLA-B:*15:02:01/Other", "CYP2C9:*25/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*25/*5;HLA-B:*15:02:01/Other", "CYP2C9:*25/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*25/*6;HLA-B:*15:02:01/Other", "CYP2C9:*25/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*25/*8;HLA-B:*15:02:01/Other", "CYP2C9:*25/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*25/*9;HLA-B:*15:02:01/Other", "CYP2C9:*3/*31;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*3/*31;HLA-B:*15:02:01/Other", "CYP2C9:*3/*3;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*3/*3;HLA-B:*15:02:01/Other", "CYP2C9:*3/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*3/*4;HLA-B:*15:02:01/Other", "CYP2C9:*3/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*3/*5;HLA-B:*15:02:01/Other", "CYP2C9:*3/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*3/*6;HLA-B:*15:02:01/Other", "CYP2C9:*3/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*3/*8;HLA-B:*15:02:01/Other", "CYP2C9:*3/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*3/*9;HLA-B:*15:02:01/Other", "CYP2C9:*31/*31;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*31/*31;HLA-B:*15:02:01/Other", "CYP2C9:*31/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*31/*4;HLA-B:*15:02:01/Other", "CYP2C9:*31/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*31/*5;HLA-B:*15:02:01/Other", "CYP2C9:*31/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*31/*6;HLA-B:*15:02:01/Other", "CYP2C9:*31/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*31/*8;HLA-B:*15:02:01/Other", "CYP2C9:*31/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*31/*9;HLA-B:*15:02:01/Other", "CYP2C9:*4/*4;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*4/*4;HLA-B:*15:02:01/Other", "CYP2C9:*4/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*4/*5;HLA-B:*15:02:01/Other", "CYP2C9:*4/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*4/*6;HLA-B:*15:02:01/Other", "CYP2C9:*4/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*4/*8;HLA-B:*15:02:01/Other", "CYP2C9:*4/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*4/*9;HLA-B:*15:02:01/Other", "CYP2C9:*5/*5;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*5/*5;HLA-B:*15:02:01/Other", "CYP2C9:*5/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*5/*6;HLA-B:*15:02:01/Other", "CYP2C9:*5/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*5/*8;HLA-B:*15:02:01/Other", "CYP2C9:*5/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*5/*9;HLA-B:*15:02:01/Other", "CYP2C9:*6/*6;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*6/*6;HLA-B:*15:02:01/Other", "CYP2C9:*6/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*6/*8;HLA-B:*15:02:01/Other", "CYP2C9:*6/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*6/*9;HLA-B:*15:02:01/Other", "CYP2C9:*8/*8;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*8/*8;HLA-B:*15:02:01/Other", "CYP2C9:*8/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*8/*9;HLA-B:*15:02:01/Other", "CYP2C9:*9/*9;HLA-B:*15:02:01/*15:02:01", "CYP2C9:*9/*9;HLA-B:*15:02:01/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "src" : "guidelineStrength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  } ],
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA450947",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA450947",
    "name" : "phenytoin"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA126",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA126",
    "symbol" : "CYP2C9",
    "name" : "cytochrome P450, family 2, subfamily C, polypeptide 9"
  }, {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA35056",
    "symbol" : "HLA-B",
    "name" : "major histocompatibility complex, class I, B"
  } ],
  "source" : "CPIC",
  "summaryHtml" : "<p>Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (\"HLA-B*15:02-positive\") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype may require reduced doses of phenytoin.</p>",
  "textHtml" : "<h3 id=\"August2014\">August 2014</h3><p><em>Accepted article preview online August 2014; Advance online publication September 2014</em></p><ul><li>Guidelines regarding the use of pharmacogenomic tests in dosing for phenytoin have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (<a href=\"/contributors/consortia/cpic_profile.jsp\">CPIC</a>).</li><li>Excerpt from the 2014 phenytoin dosing guidelines:<ul><li>\"[A]t least a 25% reduction of the recommended starting maintenance dose may be considered for CYP2C9 intermediate metabolizers with subsequent maintenance doses adjusted based on therapeutic drug monitoring and response. For CYP2C9 poor metabolizers, consider at least a 50% reduction of starting maintenance dose with subsequent maintenance doses adjusted based on therapeutic drug monitoring or response.\"</li><li>\"[R]egardless of the CYP2C9 genotype and individual's ancestry or age, if the HLA-B*15:02 test result is positive, the recommendation is to consider using an anticonvulsant other than carbamazepine and phenytoin unless the benefits of treating the underlying disease clearly outweigh the risks... Alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele and thus caution should be used in choosing alternatives to phenytoin.\"</li></ul></li><li>Download and read:<ul><li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fphenytoin%2F2014%2F25099164.pdf\" target=\"offsite\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing</a> </li><li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fphenytoin%2F2014%2F25099164-supplement.pdf\" target=\"offsite\">2014 supplement</a></li><li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fphenytoin%2F2014%2F25099164-Phenytoin_translation_table_final.xlsx\" target=\"offsite\">2014 phenytoin translation table</a></li></ul></li></ul><h3 id=\"Table1PhenytoinfosphenytointherapyrecommendationsbasedonHLABandCYP2C9phenotypegenotype\">Table 1: Phenytoin/fosphenytoin therapy recommendations based on <em>HLA-B</em> and <em>CYP2C9</em> phenotype/genotype</h3><p><em>Adapted from Tables 1 and 2 of the 2014 guideline manuscript.</em></p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><td><strong>Phenotype/Genotype</strong></td><td><strong><em>HLA-B*15:02</em> carrier</strong> <br/><em>Genotype:</em> 1 or 2 *15:02 alleles; \"positive\"</td><td><strong><em>HLA-B*15:02</em> non-carrier</strong> <br/><em>Genotype:</em> No HLA-B*15:02 alleles reported; \"negative\"</td></tr><tr><td><strong>CYP2C9 Extensive Metabolizer</strong> <br/>normal activity ~91% of patients <br/><em>Genotype:</em> An individual carrying 2 normal activity alleles <br/><em>Example diplotype:</em> *1/*1</td><td><em>Implication:</em> Increased risk of phenytoin-induced SJS/TEN. <br/><strong><em>Therapeutic Recommendation:</em>  If patient is phenytoin-naive <sup>b</sup>, do not use phenytoin/fosphenytoin.</strong> <br/><em>Strength of Recommendation: STRONG</em></td><td><em>Implication:</em> Normal phenytoin metabolism. <br/><strong><em>Therapeutic Recommendation:</em> Initiate therapy with recommended maintenance dose <sup>d</sup>.</strong> <br/><em>Strength of Recommendation: STRONG</em></td></tr><tr><td><strong>CYP2C9 Intermediate Metabolizer</strong> <br/>heterozygote ~8% of patients <br/><em>Genotype:</em>  An individual carrying one normal activity allele plus one decreased function allele <br/><em>Example diplotypes:</em> *1/*3, *1/*2</td><td><em>Implication:</em> Increased risk of phenytoin-induced SJS/TEN. <br/><strong><em>Therapeutic Recommendation:</em> If patient is phenytoin-naive <sup>b</sup>, do not use phenytoin/fosphenytoin.</strong> <br/><em>Strength of Recommendation: STRONG</em></td><td><em>Implication:</em> Reduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities. <br/><strong><em>Therapeutic Recommendation:</em> Consider 25% reduction of recommended starting maintenance dose <sup>d</sup>.  Subsequent doses should be adjusted according to therapeutic drug monitoring and response.</strong> <br/><em>Strength of Recommendation: MODERATE</em></td></tr><tr><td><strong>CYP2C9 Poor Metabolizer</strong> <br/>homozygous variant ~1% of patients <br/><em>Genotype:</em> An individual carrying 2 decreased function alleles <br/><em>Example diplotypes:</em> *2/*2, *3/*3, *2/*3</td><td><em>Implication:</em> Increased risk of phenytoin-induced SJS/TEN. <br/><strong><em>Therapeutic Recommendation:</em> If patient is phenytoin-naive <sup>b</sup>, do not use phenytoin/fosphenytoin.</strong> <br/><em>Strength of Recommendation: STRONG</em></td><td><em>Implication:</em> Reduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities. <br/><strong><em>Therapeutic Recommendation:</em> Consider 50% reduction of recommended starting maintenance dose <sup>d</sup>.  Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.</strong>  <br/><em>Strength of Recommendation: STRONG</em></td></tr></table>"
}